Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5278308
Max Phase: Preclinical
Molecular Formula: C21H23Cl2N7O2
Molecular Weight: 476.37
Associated Items:
ID: ALA5278308
Max Phase: Preclinical
Molecular Formula: C21H23Cl2N7O2
Molecular Weight: 476.37
Associated Items:
Canonical SMILES: O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2ccc3nnc(N4CCOCC4)n3n2)CC1
Standard InChI: InChI=1S/C21H23Cl2N7O2/c22-16-2-1-15(13-17(16)23)14-20(31)28-7-5-27(6-8-28)19-4-3-18-24-25-21(30(18)26-19)29-9-11-32-12-10-29/h1-4,13H,5-12,14H2
Standard InChI Key: ZGTHLDBWCSWATL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 476.37 | Molecular Weight (Monoisotopic): 475.1290 | AlogP: 2.16 | #Rotatable Bonds: 4 |
Polar Surface Area: 79.10 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 2.35 | CX LogP: 3.09 | CX LogD: 3.09 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.57 | Np Likeness Score: -2.29 |
1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ.. (2023) Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633., 86 [PMID:37148788] [10.1016/j.bmc.2023.117295] |
Source(1):